Editas Medicine (EDIT) News Today $2.88 -0.18 (-5.88%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.90 +0.02 (+0.52%) As of 07:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EDIT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Hold" from AnalystsJuly 12 at 4:21 AM | marketbeat.comEditas Surpasses Therapeutic Gene Editing Threshold in New Preclinical DataJuly 3, 2025 | msn.comEditas Medicine Inc EDIT Company Vitals - U.S. NewsJuly 1, 2025 | money.usnews.comSickle Cell Disease Treatment Market Set for Robust Growth Through 2034, Driven by Recent Clinical Pipeline Developments | DelveInsightJuly 1, 2025 | theglobeandmail.comWall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?June 28, 2025 | fool.comEditas Medicine (NASDAQ:EDIT) Upgraded by Wall Street Zen to Hold RatingJune 27, 2025 | marketbeat.comEditas Medicine Inc. Annual Cash Flow Statement - MarketWatchJune 25, 2025 | marketwatch.comEditas Medicine Inc.June 25, 2025 | barrons.comGene editors steady despite latest leadership shake-up at FDAJune 20, 2025 | msn.comLilly-Verve deal sends gene editing stocks higherJune 17, 2025 | msn.comEditas Medicine Is Great. Here's Why You Shouldn't Buy It.June 17, 2025 | msn.comEditas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of "Hold" from BrokeragesJune 17, 2025 | marketbeat.comEditas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in JuneJune 12, 2025 | globenewswire.comRFK Jr. Just Supercharged These 2 Biotech Penny StocksJune 11, 2025 | msn.comBank of America Corp DE Reduces Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)June 11, 2025 | marketbeat.comCantor Fitzgerald Comments on Editas Medicine FY2026 EarningsJune 10, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Position in Editas Medicine, Inc. (NASDAQ:EDIT)June 9, 2025 | marketbeat.comAmeriprise Financial Inc. Purchases 168,134 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)June 6, 2025 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 15,192 SharesJune 5, 2025 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) CEO Sells $26,130.24 in StockJune 5, 2025 | insidertrades.comEditas Medicine Q2 EPS Estimate Increased by Zacks ResearchJune 4, 2025 | marketbeat.comEditas Medicine Stockholders Approve Key AmendmentsJune 2, 2025 | tipranks.comEditas Medicine, Inc. (NASDAQ:EDIT) Short Interest Down 21.7% in MayJune 2, 2025 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) Shares Bought by Two Sigma Investments LPJune 2, 2025 | marketbeat.comMillennium Management LLC Cuts Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT)June 1, 2025 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) Shares Bought by Two Sigma Advisers LPMay 30, 2025 | marketbeat.comEditas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exitMay 28, 2025 | seekingalpha.com1 Stock Down 97% That Could Double, According to Wall StreetMay 25, 2025 | fool.comEditas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of "Hold" by BrokeragesMay 25, 2025 | marketbeat.com400,000 Shares in Editas Medicine, Inc. (NASDAQ:EDIT) Bought by Tang Capital Management LLCMay 21, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Boosts Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)May 19, 2025 | marketbeat.comEditas Medicine reports breakthrough in liver disease treatmentMay 15, 2025 | uk.investing.comEditas Medicine: A Cautionary Tale for InvestorsMay 15, 2025 | fool.comEditas Medicine at BofA Securities 2025: In Vivo Gene Editing FocusMay 15, 2025 | investing.comRobert W. Baird Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $4.00May 15, 2025 | marketbeat.comA new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territoryMay 15, 2025 | finance.yahoo.comEditas Medicine, Inc. (NASDAQ:EDIT) Position Raised by Balyasny Asset Management L.P.May 15, 2025 | marketbeat.comStifel Financial Corp Decreases Stake in Editas Medicine, Inc. (NASDAQ:EDIT)May 15, 2025 | marketbeat.comEditas Medicine to Present Key Preclinical Data on Gene Editing Advancements at ASGCT and TIDES ConferencesMay 14, 2025 | nasdaq.comStylus Medicine launches with $85m to advance in vivo gene editingMay 14, 2025 | msn.comEditas Medicine First Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsMay 14, 2025 | finance.yahoo.comEditas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)May 14, 2025 | seekingalpha.comEditas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in JuneMay 14, 2025 | globenewswire.comEditas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual MeetingMay 14, 2025 | globenewswire.comEditas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual MeetingMay 13, 2025 | globenewswire.comEditas Medicine, Inc.: Editas Medicine Announces First Quarter 2025 Results and Business UpdatesMay 13, 2025 | finanznachrichten.deEditas Medicine Announces First Quarter 2025 Results and Business UpdatesMay 12, 2025 | globenewswire.comEditas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal BoardMay 12, 2025 | globenewswire.comRaymond James Financial Inc. Makes New $303,000 Investment in Editas Medicine, Inc. (NASDAQ:EDIT)May 12, 2025 | marketbeat.comWells Fargo & Company MN Sells 318,436 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)May 10, 2025 | marketbeat.com Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address EDIT Media Mentions By Week EDIT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EDIT News Sentiment▼1.611.01▲Average Medical News Sentiment EDIT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EDIT Articles This Week▼25▲EDIT Articles Average Week Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Beam Therapeutics News Today CRISPR Therapeutics News Today Intellia Therapeutics News Today Dyne Therapeutics News Today Praxis Precision Medicines News Today Sionna Therapeutics News Today Niagen Bioscience News Today Spyre Therapeutics News Today Pharvaris News Today Nurix Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EDIT) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EDIT Stock Alerts